Belite Bio, Inc
BLTE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001889109
In the last 90 days, Belite Bio, Inc insiders filed 0 open-market purchases and 4 sales; 80 institutions reported holding it in 13F filings for Q2 2026, worth $1.44B in total; superinvestors Maverick Capital and Duquesne Family Office hold it.
Key figures
- Market capADS ratio not in SEC data
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $32.3M in total
- 4
- 13F holdersQ2 2026, +4 vs. previous quarter
- 80
- 13F valueReported value at the end of Q2 2026
- $1.44B
- Superinvestors holdingAt the end of Q2 2026
- 2
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$77.6M
- No comparable prior period
- Free cash flow, FY2025
- -$37.1M
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 1.38M
- Shares sold short
- Change
- +113.0K
- +8.9% vs. previous
- Days to cover
- 9.96
- At average daily volume
Superinvestors holding BLTE, Q2 2026
Go to the superinvestors tab2 superinvestors report holding Belite Bio, Inc on Form 13F. Percentages are the stock's share of each portfolio.
Duquesne Family Office
Stanley Druckenmiller
0.4%
Belite Bio, Inc's share of the portfolio
- Shares
- 106,100
- Value
- $16.3M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Belite Bio, Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 16, 2026 (view filing)7:13 PM ET | Nov 12 | 4 days | Scholl Hendrik PeterChief Medical Officer | SSaleAmerican depositary share | −2.00K | $165.99 | −$332.0K | −13.8%12.5K after | 4 lots10b5-1 |
| Oct 5, 2026 (view filing)7:27 PM ET | Oct 1 | 4 days | Scholl Hendrik PeterChief Medical Officer | SSaleAmerican depositary share | −500 | $165.32 | −$82.7K | −3.3%14.5K after | 8 lots10b5-1 |
| Sep 9, 2026 (view filing)7:39 PM ET | Sep 4-8 | 5 days | Lin Yu-HsinChief Executive Officer | SSaleAmerican depositary share | −100.4K | $190.00 | −$19.1M | −58.9%70.1K after | 19 lots10b5-1 |
| Sep 9, 2026 (view filing)7:38 PM ET | Sep 4-8 | 5 days | Chuang Hao-YuanChief Financial Officer | SSaleAmerican depositary share | −67.4K | $189.98 | −$12.8M | −72.1%26.0K after | 19 lots10b5-1 |
| Aug 14, 2026 (view filing)6:10 AM ET | Aug 12 | 2 days | Chuang Hao-YuanChief Financial Officer | SSaleAmerican depositary share | −367 | $180.35 | −$66.2K | −0.4%93.4K after | 2 lots10b5-1 |
| Aug 14, 2026 (view filing)6:10 AM ET | Aug 12 | 2 days | Lin Yu-HsinChief Executive Officer | SSaleAmerican depositary share | −365 | $180.35 | −$65.8K | −0.2%170.6K after | 2 lots10b5-1 |
| Jun 22, 2026 (view filing) | Jun 18 | 4 days | Scholl Hendrik PeterChief Medical Officer | SSaleAmerican depositary share | −10.0K | $145.24 | −$1.45M | −40.0%15.0K after | 5 lots |
| Jun 17, 2026 (view filing) | Jun 16 | 1 day | Scholl Hendrik PeterChief Medical Officer | SSaleAmerican depositary share | −10.0K | $140.57 | −$1.41M | −28.6%25.0K after | 8 lots |
| May 8, 2026 (view filing) | May 7 | 1 day | Mata Nathan L.Chief Scientific Officer | SSaleAmerican depositary share | −666 | $153.21 | −$102.0K | −100.0%0 after | 4 lots10b5-1 |
| May 7, 2026 (view filing) | May 6 | 1 day | Mata Nathan L.Chief Scientific Officer | SSaleAmerican depositary share | −1.00K | $153.84 | −$153.8K | −60.0%666 after | 6 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 80 holdersThe largest institutional positions in Belite Bio, Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Darwin Global Management, Ltd. | 3,077,219 | $456.6M | 12.14% | +19,807+0.6% | Added |
| Paradigm Biocapital Advisors LP | 1,232,877 | $189.8M | 3.55% | +118,093+10.6% | Added |
| RTW Investments, LP | 715,332 | $110.2M | 0.94% | 00.0% | Unchanged |
| Millennium Management LLC | 494,564 | $76.2M | 0.05% | −75,524−13.2% | Reduced |
| Maverick Capital LtdSuperinvestorMaverick Capital | 396,311 | $61.0M | 0.55% | +396,311 | New |
| Eventide Asset Management, LLC | 390,829 | $60.2M | 0.80% | +33,179+9.3% | Added |
| Deerfield Management Company, L.P. (Series C) | 357,199 | $55.0M | 0.57% | +53,186+17.5% | Added |
| Holocene Advisors, LP | 251,035 | $38.7M | 0.09% | −243,460−49.2% | Reduced |
| Logos Global Management LP | 250,000 | $38.5M | 1.66% | +250,000 | New |
| Morgan Stanley | 235,071 | $36.2M | 0.00% | +33,662+16.7% | Added |
Holders of 5% or more of BLTE
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Belite Bio, Inc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Lin Bioscience International Ltd. | 13G | 53.70%17.1M shares | – | Feb 14, 20233 filings | Jan 21, 2025 | SEC |
| Darwin Global Management, Ltd. | 13G/A | 8.10%3.03M shares | +1.10 ppfrom 7.00% | Dec 10, 20252 filings | Feb 17, 2026 | SEC |